A Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - "FIR"
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
First received: May 1, 2013
Last updated: June 16, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||July 2017|
|Primary Completion Date:||January 2015 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||June 15, 2016|